![](/img/cover-not-exists.png)
A phase 3, randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy and safety of eliglustat in patients with Gaucher disease type 1 (ENGAGE): Results after 9months of treatment
Mistry, Pramod, Lukina, Elena, Dridi, Marie-Françoise Ben, Amato, Dominick, Baris, Hagit, Dasouki, Majed, Ghosn, Marwan, Mehta, Atul, Packman, Seymour, Pastores, Gregory, Petakov, Milan, Peterschmitt,Volume:
108
Language:
english
Journal:
Molecular Genetics and Metabolism
DOI:
10.1016/j.ymgme.2012.11.171
Date:
February, 2013
File:
PDF, 77 KB
english, 2013